These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 22510096)

  • 21. Pharmacokinetic interactions between the hepatitis C virus protease inhibitor boceprevir and ritonavir-boosted HIV-1 protease inhibitors atazanavir, darunavir, and lopinavir.
    Hulskotte EG; Feng HP; Xuan F; van Zutven MG; Treitel MA; Hughes EA; O'Mara E; Youngberg SP; Wagner JA; Butterton JR
    Clin Infect Dis; 2013 Mar; 56(5):718-26. PubMed ID: 23155151
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Focus on drug interactions: the challenge of treating hepatitis C virus infection with direct-acting antiviral drugs in the HIV-positive patient.
    Rodríguez-Torres M
    Curr Opin Infect Dis; 2013 Feb; 26(1):50-7. PubMed ID: 23242341
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Direct-acting antivirals for hepatitis C virus infections in patients co-infected with human immunodeficiency virus.
    Piroth L
    Clin Res Hepatol Gastroenterol; 2011 Dec; 35 Suppl 2():S75-83. PubMed ID: 22248699
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Future perspectives: towards interferon-free regimens for HCV.
    Gane E
    Antivir Ther; 2012; 17(6 Pt B):1201-10. PubMed ID: 23186654
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Triple combination therapy for hepatitis C with telaprevir exhibits greater early antiviral activity than with boceprevir.
    Benito JM; Sánchez-Parra C; Maida I; Aguilera A; Rallón NI; Rick F; Labarga P; Fernández-Montero JV; Barreiro P; Soriano V
    Antivir Ther; 2013; 18(5):709-15. PubMed ID: 23645335
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Telaprevir: a hepatitis C NS3/4A protease inhibitor.
    Matthews SJ; Lancaster JW
    Clin Ther; 2012 Sep; 34(9):1857-82. PubMed ID: 22951253
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Prevalence of potential interactions between antiretroviral therapy and boceprevir or telaprevir in human immunodeficiency virus-hepatitis C virus coinfected patients].
    González-Colominas E; Solà R; Barrantes-González M; Salas E
    Enferm Infecc Microbiol Clin; 2013 May; 31(5):350-1. PubMed ID: 23182365
    [No Abstract]   [Full Text] [Related]  

  • 28. [Drug-drug interaction with telaprevir or boceprevir in liver transplant patients: about four cases].
    Delaborde L; Logerot S; Fonrose X
    Therapie; 2014; 69(6):491-7. PubMed ID: 25320939
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New agents for the treatment of hepatitis C in patients co-infected with HIV.
    Munteanu DI; Rockstroh JK
    Ther Adv Infect Dis; 2013 Apr; 1(2):71-80. PubMed ID: 25165545
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C.
    Cammà C; Petta S; Enea M; Bruno R; Bronte F; Capursi V; Cicchetti A; Colombo GL; Di Marco V; Gasbarrini A; Craxì A;
    Hepatology; 2012 Sep; 56(3):850-60. PubMed ID: 22454336
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Will direct-acting antivirals make a difference in HIV-HCV coinfected patients?
    Bruno R; Fagiuoli S; Sacchi P
    Expert Rev Anti Infect Ther; 2011 Sep; 9(9):699-701. PubMed ID: 21905777
    [No Abstract]   [Full Text] [Related]  

  • 32. Key drug-drug interactions with direct-acting antiviral in HIV-HCV coinfection.
    El-Sherif O; Khoo S; Solas C
    Curr Opin HIV AIDS; 2015 Sep; 10(5):348-54. PubMed ID: 26248122
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The importance of drug-drug interactions in the DAA era.
    Back D; Else L
    Dig Liver Dis; 2013 Sep; 45 Suppl 5():S343-8. PubMed ID: 24091114
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antiviral drug advances in the treatment of human immunodeficiency virus (HIV) and chronic hepatitis C virus (HCV).
    Wegzyn CM; Wyles DL
    Curr Opin Pharmacol; 2012 Oct; 12(5):556-61. PubMed ID: 22770811
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Challenges in the treatment of chronic hepatitis C in the HIV/HCV-coinfected patient.
    Rodríguez-Torres M
    Expert Rev Anti Infect Ther; 2012 Oct; 10(10):1117-28. PubMed ID: 23199398
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Drug-drug interactions in the treatment of HCV among people who inject drugs.
    Mauss S; Klinker H
    Clin Infect Dis; 2013 Aug; 57 Suppl 2():S125-8. PubMed ID: 23884060
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and tolerance of telaprevir in HIV-hepatitis C virus genotype 1-coinfected patients failing previous antihepatitis C virus therapy: 24-week results.
    Lacombe K; Valin N; Stitou H; Gozlan J; Thibault V; Boyd A; Poirier JM; Meynard JL; Valantin MA; Bottero J; Girard PM
    AIDS; 2013 May; 27(8):1356-9. PubMed ID: 23925383
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Direct-acting antiviral (DAA) actions in treatment-naïve patients.
    Hézode C
    Clin Res Hepatol Gastroenterol; 2011 Dec; 35 Suppl 2():S52-8. PubMed ID: 22248695
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Efficacy of triple therapy in patients with chronic hepatitis C not treated and patients previously treated ineffectively].
    Kozielewicz D; Halota W; Dybowska D
    Przegl Epidemiol; 2012; 66(1):49-54. PubMed ID: 22708298
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of hepatitis C and liver fibrosis on antiretroviral plasma drug concentrations in HIV-HCV co-infected patients: the HEPADOSE study.
    Dominguez S; Ghosn J; Peytavin G; Guiguet M; Tubiana R; Valantin MA; Murphy R; Bricaire F; Benhamou Y; Katlama C
    J Antimicrob Chemother; 2010 Nov; 65(11):2445-9. PubMed ID: 20813809
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.